Answers are grounded in this paper and cite their sources.
Antibody-drug conjugates (ADCs) are increasingly used to treat recurrent high grade serous ovarian cancer (HGSOC), yet their effects on tumor biology and subsequent treatment response remain poorly understood. We evaluated the short-term effects of ADCs and their respective payloads on ADC receptor expression and developed payload resistant HGSOC cell lines to determine how acquired payload resistance influences response to subsequent ADC therapy. Matched platinum sensitive and resistant HGSOC cell lines were exposed to trastuzumab deruxtecan (T-DXd) and mirvetuximab soravtansine (MIRV), or their respective payloads, DXd and DM4. DXd and DM4 resistant cell lines were generated through sequential payload dose escalation and characterized for ADC receptor expression and response to T-DXd, MIRV, and sacituzumab govitecan (SG). Short-term T-DXd and MIRV exposure reduced their respective targets in chemosensitive cells and altered several clinically relevant ADC receptors. DXd and DM4 resistant cell lines were developed and confirmed resistant. Notably, DM4 resistant cells showed increased T-DXd sensitivity, whereas DXd resistant cells exhibited reduced sensitivity to MIRV and SG. These findings demonstrate that ADC exposure dynamically alters receptor expression and that acquired payload resistance can differentially influence subsequent ADC response. Further investigation may identify biomarkers of ADC resistance and inform upon ADC sequencing strategies in HGSOC.
No takes yet. Share an insight, caveat, or question.
Pearce et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: